InMed Pharmaceuticals (INM) Other Working Capital Changes (2022 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Other Working Capital Changes of -$110066.0 for Q1 2026, up 1.11% year-over-year from -$108861.9 in Q1 2025, and little changed quarter-over-quarter from -$109917.0 in Q4 2025.
InMed Pharmaceuticals (INM) Other Working Capital Changes (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Other Working Capital Changes history runs 4 years deep, the most recent figure standing at -$110066.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 1.11% year-over-year to -$110066.0; the TTM figure through Mar 2026 stood at -$442054.0 (down 950.26% YoY), while the FY2025 annual figure was -$429880.0, down 2558.34% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$110066.0, roughly flat from -$109917.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $495104.0 in Q4 2024, with the low at -$328867.0 in Q3 2024.
- The 4-year median for Other Working Capital Changes is -$8902.0 (2022), against an average of $30502.8.
- Peak annual rise in Other Working Capital Changes reached 350.38% in 2024, while the deepest fall reached 187.61% in 2024.
- InMed Pharmaceuticals' Other Working Capital Changes stood at $111194.0 in 2023, then tumbled by 187.61% to -$97418.0 in 2024, then retreated by 12.83% to -$109917.0 in 2025, then declined by 0.14% to -$110066.0 in 2026.
- Business Quant data shows INM's Other Working Capital Changes at -$110066.0 in Q1 2026, -$109917.0 in Q4 2025, and -$107412.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42,225.00 |
| Mar 31, 2026 | -42,225.00 |
| Mar 31, 2026 | -42,225.00 |
| Dec 31, 2025 | 467,042.00 |
| Dec 31, 2025 | 467,042.00 |
| Dec 31, 2025 | 467,042.00 |
| Sep 30, 2025 | -129,992.00 |
| Sep 30, 2025 | -129,992.00 |
| Sep 30, 2025 | -129,992.00 |
| Mar 31, 2025 | -104,656.00 |
| Mar 31, 2025 | -104,656.00 |
| Mar 31, 2025 | -104,656.00 |
| Dec 31, 2024 | 495,104.00 |
| Dec 31, 2024 | 495,104.00 |
| Dec 31, 2024 | 495,104.00 |
| Sep 30, 2024 | -328,867.00 |
| Sep 30, 2024 | -328,867.00 |
| Sep 30, 2024 | -328,867.00 |
| Mar 31, 2024 | -28,656.00 |
| Mar 31, 2024 | -28,656.00 |